Nazan Dolapoğlu1,2, Banu Pınar Şarer Yürekli3, Mehmet Çağdaş Eker2, Hayriye Elbi2. 1. Balıkesir Atatürk State Hospital, Psychiatry Clinic, Balıkesir, Turkey. 2. Ege University Medical School, Department of Psychiatry, İzmir, Turkey. 3. Ege University Medical School, Department of Clinical Endocrinology and Metabolism, İzmir, Turkey.
Abstract
INTRODUCTION: Agouti-Related Peptide (AgRP) is expressed primarily in the hypothalamic arcuate nucleus, stimulates appetite and decreases metabolism and energy expenditure. The aim of our study is to evaluate the relationship between serum Agouti-Related Peptide (AgRP) levels and metabolic syndrome in euthymic bipolar patients. METHODS: Forty euthymic bipolar patients who used only mood stabilizer for at least three months and 40 healthy volunteers as control group were included in the study. We measured fasting blood glucose levels and serum levels of AgRP, total cholesterol, triglyceride, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) of all participants. The main outcome measure was the difference between patients and control groups in terms of metabolic syndrome frequency and the relationship between serum AgRP level and metabolic syndrome is also investigated. RESULTS: The metabolic syndrome was significantly more common in euthymic bipolar patients than in control group (p=0.039). Additionally, levels of blood glucose and triglyceride were significantly higher in the patient group than in the control group (p=0.006 and 0.01 respectively). Serum AgRP levels did not differ between the patient and control groups (p=0.35). Also, in euthymic bipolar patients, there was no significant difference in serum AgRP levels between patients with metabolic syndrome and those without (p=0.754). CONCLUSION: We found significantly higher frequency of metabolic syndrome in euthymic bipolar patients than in the control group. However, there was no significant difference in the levels of serum AgRP between bipolar patients with and without metabolic syndrome in either study groups. Copyright:
INTRODUCTION: Agouti-Related Peptide (AgRP) is expressed primarily in the hypothalamic arcuate nucleus, stimulates appetite and decreases metabolism and energy expenditure. The aim of our study is to evaluate the relationship between serum Agouti-Related Peptide (AgRP) levels and metabolic syndrome in euthymic bipolar patients. METHODS: Forty euthymic bipolar patients who used only mood stabilizer for at least three months and 40 healthy volunteers as control group were included in the study. We measured fasting blood glucose levels and serum levels of AgRP, total cholesterol, triglyceride, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) of all participants. The main outcome measure was the difference between patients and control groups in terms of metabolic syndrome frequency and the relationship between serum AgRP level and metabolic syndrome is also investigated. RESULTS: The metabolic syndrome was significantly more common in euthymic bipolar patients than in control group (p=0.039). Additionally, levels of blood glucose and triglyceride were significantly higher in the patient group than in the control group (p=0.006 and 0.01 respectively). Serum AgRP levels did not differ between the patient and control groups (p=0.35). Also, in euthymic bipolar patients, there was no significant difference in serum AgRP levels between patients with metabolic syndrome and those without (p=0.754). CONCLUSION: We found significantly higher frequency of metabolic syndrome in euthymic bipolar patients than in the control group. However, there was no significant difference in the levels of serum AgRP between bipolar patients with and without metabolic syndrome in either study groups. Copyright:
Authors: Roger S McIntyre; Hanna O Woldeyohannes; Joanna K Soczynska; Andrew Miranda; Angela Lachowski; Samantha S Liauw; Talia Grossman; Maria T Lourenco; Byungsu Kim; Mohammad T Alsuwaidan; Sidney H Kennedy Journal: Adv Ther Date: 2010-09-24 Impact factor: 3.845
Authors: Eva Tsaousidou; Lars Paeger; Bengt F Belgardt; Martin Pal; Claudia M Wunderlich; Hella Brönneke; Ursel Collienne; Brigitte Hampel; F Thomas Wunderlich; Marc Schmidt-Supprian; Peter Kloppenburg; Jens C Brüning Journal: Cell Rep Date: 2014-11-13 Impact factor: 9.423
Authors: Fernanda Pedrotti Moreira; Karen Jansen; Taiane de Azevedo Cardoso; Thaíse Campos Mondin; Pedro Vieira da Silva Magalhães; Flávio Kapczinski; Luciano Dias de Mattos Souza; Ricardo Azevedo da Silva; Jean Pierre Oses; Carolina David Wiener Journal: J Psychiatr Res Date: 2017-04-02 Impact factor: 4.791
Authors: Hui Hua Chang; Chen Hsi Chou; Po See Chen; Po Wu Gean; Hui Chun Huang; Chia Yin Lin; Yen Kuang Yang; Ru Band Lu Journal: J Affect Disord Date: 2009-02-04 Impact factor: 4.839